Randomized Phase II Trial of Topotecan plus M6620 (VX-970) vs. Topotecan alone in Patients with Relapsed Small-Cell Lung Cancer | NYU Langone Health

Randomized Phase II Trial of Topotecan plus M6620 (VX-970) vs. Topotecan alone in Patients with Relapsed Small-Cell Lung Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Small Cell Lung Cancer (sclc)
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Patients enrolled to the primary cohort must have limited- or extensive-disease SCLC at diagnosis, with relapse at study entry with measurable disease at random assignment per RECIST 1.1. 2) Patients with extrapulmonary small cell cancers. 3) Patients must have adequate organ and marrow function.

You may not be eligible for this study if the following are true:

1) Patients with symptomatic brain metastasis are not eligible due to their extremely poor prognosis and since it is unclear whether the investigational agent penetrates the blood brain barrier. 2) Patients who have received prior topotecan therapy. 3) Patients who have had chemotherapy or radiotherapy within 3 weeks prior to enrollment.